Clinical trials: Oral Neoplasm, active
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Trial name
- NCT05136196
- Testing
- Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate
- Where
- 231 sites in United States
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement…
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT06589804
- Testing
- Biospecimen Collection, Cetuximab, Computed Tomography
- Where
- 201 sites in United States
- Volunteers
- 158 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Background: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Prostate cancer is the most common cancer in men in the United States.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma
- Trial name
- NCT07667400
- Testing
- SX-682, DTX
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This randomized phase III trial studies chemotherapy to see how well it works with or without bevacizumab in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or that has spread to other…
- Conditions
- Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma
- Trial name
- NCT00588770
- Testing
- Bevacizumab, Carboplatin, Cisplatin
- Where
- 779 sites in United States, Puerto Rico and 1 more
- Volunteers
- 403 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy [cisplatin and carboplatin] plus radiation therapy) after surgery in treating patients with head and neck squamous cell…
- Conditions
- Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT04671667
- Testing
- Carboplatin, Cisplatin, Computed Tomography
- Where
- 178 sites in United States
- Volunteers
- 188 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation
Oral Care Program for Mouth Side Effects During Head and Neck Radiation Therapy
People having radiation therapy to the head and neck often develop painful mouth problems - mouth sores, dry mouth, mouth pain, trouble eating and drinking, and changes in taste.
- Conditions
- Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation, Stomatitis (Oral Mucositis), Xerostomia Due to Radiotherapy
- Trial name
- OSEM (NCT07885033)
- Testing
- ORAL CARE PRODUCT KIT
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- UNCANCER LLC
Mucositis Oral, Head and Neck Cancer
Photobiomodulation for the Prevention of Radiation Induced Oral Mucositis
Radiotherapy for head and neck cancer can cause severe mucositis (ulcers in the mouth) and pain. Photobiomodulation (Light therapy) will be used before and during radiotherapy to try to reduce the occurence and severity of…
- Conditions
- Mucositis Oral, Head and Neck Cancer, Radiation Dermatitis
- Trial name
- NCT04671862
- Testing
- Photobiomodulation
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Ottawa Hospital Research Institute
HNSCC, SCC - Squamous Cell Carcinoma
Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)
The goal of this clinical trial is to learn whether intratumoral (injected directly into the tumor) fluorescently labeled nivolumab (nivo800) is safe for adults with head and neck squamous cell carcinoma (HNSCC) who are scheduled…
- Conditions
- HNSCC, SCC - Squamous Cell Carcinoma, Oral Cancer
- Trial name
- NCT07741565
- Testing
- Nivolumab-IRDye800
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma
Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma
The goal of this clinical trial is to learn whether using two imaging agents-Panitumumab-IRDye800 (Pan800) and[18F]NOTA-ABY-030-is safe and feasible for helping surgeons identify tumors and cancer-containing lymph nodes during…
- Conditions
- HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Surgery
- Trial name
- NCT07741643
- Testing
- Panitumumab-IRDye800, [18F]NOTA-ABY-030
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Hearing Disorder, Oral Mucosal Disease
Biospecimen Procurement for Head and Neck Disorders
Background: Researchers want to learn more about head and neck disorders. Understanding these disorders could help them find better treatments. To do this, they are collecting tissue samples for research.
- Conditions
- Hearing Disorder, Oral Mucosal Disease, Pharyngeal Neoplasm, Head and Neck Neoplasms
- Trial name
- NCT03429036
- Where
- 9 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of Oral Cavity, Pharynx Carcinoma
Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose Radiotherapy
Non-commercial clinical study to assess: 1. efficacy of iCHRTL in patients with advanced squamous cell carcinoma of oral cavity, pharynx carcinoma, larynx carcinoma or paranasal sinus carcinoma. 2.
- Conditions
- Squamous Cell Carcinoma of Oral Cavity, Pharynx Carcinoma, Larynx Carcinoma, Paranasal Sinus Carcinoma
- Trial name
- iCHRTL (NCT05992610)
- Testing
- Chemotherapy (carboplatin+paclitaxel) with concomitant low dose ionizing radiotherapy
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasal Cavity Squamous Cell Carcinoma
- Trial name
- NCT06980038
- Testing
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Hnscc, Head and Neck
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
The goal of this Phase 1 clinical trial is to evaluate the safety and feasibility of nivolumab-IRDye800CW (nivo800) as a molecular imaging agent in adults with biopsy-confirmed or presumed head and neck squamous cell carcinoma…
- Conditions
- Hnscc, Head and Neck, Squamous Cell Cancer, Squamous Carcinoma
- Trial name
- NCT07460765
- Testing
- Nivo800, Nivolumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Dysplasia, Lip and Oral Cavity Carcinoma
Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders
This early phase I trial studies how well multimodal imaging works for surveillance in patients with oral potentially malignant disorders.
- Conditions
- Dysplasia, Lip and Oral Cavity Carcinoma, Oral Disorder, Premalignant Lesion
- Trial name
- NCT02790853
- Testing
- Biopsy, Fluorescence Imaging, High-Resolution Microendoscopy
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- M.D. Anderson Cancer Center
Oral Mucosa Discomfort, Pediatric Cancer
Music Therapy for Oral Mucositis Pain in Pediatric Patients
This mixed-methods pilot study will examine the effect of music therapy on oral mucositis pain in pediatric oncology patients. Oral mucositis, characterized by painful ulcerative lesions in the mouth, is a common side effect of…
- Conditions
- Oral Mucosa Discomfort, Pediatric Cancer, Mucositis Oral
- Trial name
- NCT07653360
- Testing
- Semi-Structured Interviews
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy…
- Conditions
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT07195734
- Testing
- Biospecimen Collection, Carboplatin, Cemiplimab
- Where
- 113 sites in United States
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
This phase I trial investigates the side effects and best dose of peposertib when given together with radiation therapy in treating patients with head and neck cancer that has spread to other places in the body (advanced) who…
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT04533750
- Testing
- Intensity-Modulated Radiation Therapy, Peposertib
- Where
- 27 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Head & Neck Cancer, Oral Mucositis
A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.
Most patients who receive radiation therapy for head and neck cancer develop painful sores in the mouth called oral mucositis. For many of them, these sores are severe and result in debilitating pain.
- Trial name
- BEAM-Pain (NCT07672236)
- Testing
- BupiZenge 25 mg, Lidocaine viscous 2%
- Where
- 11 sites in Denmark, Germany and 2 more
- Volunteers
- 150 people
- Sponsor
- OncoZenge AB
Nutritional Deterioration, Malignant Solid Tumor
Benefits of Nutritional Supplement in Cancer Care
This is an exploratory, open-label, 2:1 randomized controlled trial conducted across collaborating oncology clinics and extended research networks in Hong Kong.
- Conditions
- Nutritional Deterioration, Malignant Solid Tumor, Cancer Cachexia, Cancer Malnutrition
- Trial name
- NCT07869290
- Testing
- Nutrition supplement, Digital Health App Monitoring, Individualized Dietitian Consultation
- Volunteers
- 100 people
- Sponsor
- The Hong Kong Polytechnic University
Oropharynx Cancer, Oral Cavity
Oncology, Undernutrition and Sensoriality: Links, Mechanisms and Levers for Action
Cancers of the upper aerodigestive tract account for around 4% of all malignant tumours worldwide. Colon and liver cancer are the most common digestive cancers.
- Conditions
- Oropharynx Cancer, Oral Cavity, Colon Cancer, Liver Cancer
- Trial name
- ONDES (NCT06600295)
- Testing
- tests/questionnaires, biological samples, evaluation
- Where
- France
- Volunteers
- 306 people
- Sponsor
- Centre Hospitalier Universitaire Dijon